Chronic myeloid leukaemia - The choice of therapy and future perspectives

Angelo M. Carella; Clara Dellepiane; Davide Lovera; Adalberto Ibatici; Chiara Ghiggi; Andrea Carella; Germana Beltrami

doi:10.17925/EOH.2015.11.01.25

Chronic myeloid leukaemia - The choice of therapy and future perspectives

Angelo M. Carella, Clara Dellepiane, Davide Lovera, Adalberto Ibatici, Chiara Ghiggi, Andrea Carella, Germana Beltrami

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article

Abstract

Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.

Original language	English
Pages (from-to)	25-29
Number of pages	5
Journal	European Oncology and Haematology
Volume	11
Issue number	1
DOIs	https://doi.org/10.17925/EOH.2015.11.01.25
Publication status	Published - Jun 1 2015

Keywords

Chronic myeloid leukaemia
New therapeutic strategies
Stem cell biology
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.17925/EOH.2015.11.01.25

Fingerprint Dive into the research topics of 'Chronic myeloid leukaemia - The choice of therapy and future perspectives'. Together they form a unique fingerprint.

Cite this

Carella, A. M., Dellepiane, C., Lovera, D., Ibatici, A., Ghiggi, C., Carella, A., & Beltrami, G. (2015). Chronic myeloid leukaemia - The choice of therapy and future perspectives. European Oncology and Haematology, 11(1), 25-29. https://doi.org/10.17925/EOH.2015.11.01.25

@article{20bfc8e1f9b9430aa811a78865b533d9,

title = "Chronic myeloid leukaemia - The choice of therapy and future perspectives",

abstract = "Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.",

keywords = "Chronic myeloid leukaemia, New therapeutic strategies, Stem cell biology, Tyrosine kinase inhibitors",

author = "Carella, {Angelo M.} and Clara Dellepiane and Davide Lovera and Adalberto Ibatici and Chiara Ghiggi and Andrea Carella and Germana Beltrami",

year = "2015",

month = jun,

day = "1",

doi = "10.17925/EOH.2015.11.01.25",

language = "English",

volume = "11",

pages = "25--29",

journal = "European Oncology and Haematology",

issn = "2045-5275",

publisher = "Touch Digital Media",

number = "1",

}

TY - JOUR

T1 - Chronic myeloid leukaemia - The choice of therapy and future perspectives

AU - Carella, Angelo M.

AU - Dellepiane, Clara

AU - Lovera, Davide

AU - Ibatici, Adalberto

AU - Ghiggi, Chiara

AU - Carella, Andrea

AU - Beltrami, Germana

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.

AB - Recently, the advent of imatinib has opened a new era in the treatment of chronic myeloid leukaemia (CML), leading to an impressive increase in overall survival rates. Today, many CML patients can expect to survive, if properly managed, likely similar to the general population. Recent progresses in CML stem cell biology have identified new leukogenetic pathways and therapeutic strategies that can be used to target the CML stem cell compartment. These studies have opened new perspectives in CML therapy and have highlighted major strategies for treating, and possibly eradicating, CML in the upcoming years.

KW - Chronic myeloid leukaemia

KW - New therapeutic strategies

KW - Stem cell biology

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84973652216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973652216&partnerID=8YFLogxK

U2 - 10.17925/EOH.2015.11.01.25

DO - 10.17925/EOH.2015.11.01.25

M3 - Article

AN - SCOPUS:84973652216

VL - 11

SP - 25

EP - 29

JO - European Oncology and Haematology

JF - European Oncology and Haematology

SN - 2045-5275

IS - 1

ER -